Recent advances in Alzheimer’s diagnostics have ushered in a new generation of blood tests that promise faster, simpler detection of the disease’s biological markers. But according to Dr. William T. Hu, the scientific promise does not yet translate into a clear clinical path—especially across diverse patient populations. Dr. Hu’s research found that some blood-based biomarkers, while reasonably accurate in White patients, showed much lower accuracy in Black individuals, underscoring that “there’s a high chance that they actually won’t have Alzheimer’s” despite a positive result.